SUPERNUS PHARMACEUTICALS, INC. (SUPN) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Latest close $28.96 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Third Avenue Management · Axiom Investors — 2 tracked funds hold SUPN. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Third Avenue Management | 1.14% | 152,724 | HELD Q3 filed Nov 13 |
| Axiom Investors | 0.04% | 94,465 | TRIMMED (-42.4%) Q3 filed Nov 12 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -27.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 333 of 8,857 filers |
| Long-only filers among them | 331 |
| Change vs 2026 Q1 | +14 net · 321 entered · 307 exited |
| Shares reported, all filers | 60,230,061 |
| Reported value, all filers | $2.7B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $719.0M |
| Net income · FY2025 | $-38.5M |
| Total assets · FY2025 | $1.5B |
| Shares outstanding | 58,235,716 |
| Market cap (at latest close) | $1.7B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 27, 2026.
| Shares short · Oct 15, 2026 | 4,043,677 |
| Share of shares outstanding | 6.94% |
| Days to cover | 4.93 |
Shares short at recent settlements — Jul 31, 2026: 4.8M · Aug 14, 2026: 4.1M · Aug 31, 2026: 4.7M · Sep 15, 2026: 5.0M · Sep 30, 2026: 5.0M · Oct 15, 2026: 4.0M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 27, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 27, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Mar 17, 2026 | PADMANABH P BHATT | Officer | 57,250 | $2.9M | Mar 17, 2026 | SEC filing |
| Mar 16, 2026 | PADMANABH P BHATT | Officer | 50,000 | $2.5M | Mar 16, 2026 | SEC filing |
| Mar 13, 2026 | THE KBT TRUST U/A DTD 12/30/2010 | Director, Officer | 35,000 | $1.8M | Mar 13, 2026 | SEC filing |
| Mar 12, 2026 | FREDERICK M HUDSON | Director | 5,369 | $271.8K | Mar 12, 2026 | SEC filing |
| Mar 10, 2026 | WILLIAM TODD HORICH | Officer | 4,439 | $244.1K | Mar 10, 2026 | SEC filing |
| Mar 9, 2026 | WILLIAM TODD HORICH | Officer | 4,438 | $239.7K | Mar 9, 2026 | SEC filing |
| Mar 9, 2026 | FRANK MOTTOLA | Officer | 1,623 | $87.1K | Mar 9, 2026 | SEC filing |
| Mar 6, 2026 | GEORGES GEMAYEL | Director | 8,787 | $465.8K | Mar 6, 2026 | SEC filing |
| Mar 5, 2026 | GEORGES GEMAYEL | Director | 10,000 | $537.1K | Mar 5, 2026 | SEC filing |
| Feb 19, 2026 | BETHANY SENSENIG | Director | 4,475 | $224.6K | Feb 19, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Integrated Core Strategies (US) LLC | SC 13G/A | 3,605,227 | 6.2% | Jun 30, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 2,900,884 | 5.0% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Portfolio Management | SC 13G | 3,263,309 | 5.7% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 18, 2026 | Integrated Core Strategies (US) LLC | SC 13G/A | 2,817,883 | 4.9% | Feb 11, 2026 | SEC filing |
| Feb 17, 2026 | Armistice Capital, LLC | SC 13G/A | 2,764,000 | 4.8% | Dec 31, 2025 | SEC filing |
| Feb 2, 2026 | Millennium Management LLC | SC 13G | 3,036,123 | 5.3% | Jan 26, 2026 | SEC filing |
| Jan 21, 2026 | Dimensional Fund Advisors LP | SC 13G/A | 2,712,341 | 4.7% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | Armistice Capital, LLC | SC 13G/A | 2,836,000 | 5.1% | Sep 30, 2025 | SEC filing |
| Aug 15, 2025 | Armistice Capital, LLC | SC 13G/A | 4,812,000 | 8.6% | Jun 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 54 Lobbying Disclosure Act filings named this company as client, 2018–2026; most common issues: Health Issues (54), Medicare/Medicaid (24).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
This stock does not currently pass any tracked screen.
Also held by the tracked funds that hold SUPN — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 2, 2026 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | SEC filing |
| Nov 2, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.01 Completion of Acquisition or Disposition of Assets · 2.03 Creation of a Direct Financial Obligation · 3.03 Material Modification to Rights of Security Holders · 5.01 Changes in Control of Registrant · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 29, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on SUPN
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.